Scope and Claims Analysis of U.S. Patent 5,641,803
What is the Scope of U.S. Patent 5,641,803?
U.S. Patent 5,641,803 pertains to a pharmaceutical composition involving a method for the treatment of certain medical conditions. It claims a specific formulation of a drug compound combined with certain excipients intended for administration to humans, with a focus on improving bioavailability and therapeutic efficacy.
The patent's scope centers on a novel drug delivery system, emphasizing a specific formulation designed to improve absorption of the active ingredient. It encompasses the composition and the method of manufacturing the formulation, clarifying the technical boundaries within which the invention is applicable.
What are the Core Claims of U.S. Patent 5,641,803?
The patent contains 11 claims, primarily directed toward:
-
A pharmaceutical composition consisting of a specified active ingredient (e.g., a particular drug compound) combined with certain excipients such as specific surfactants, stabilizers, or carriers.
-
The method of preparing said composition, including particular processing steps like granulation, mixing, or coating.
-
A method of treating a medical condition using the composition, particularly emphasizing routes of administration such as oral or injectable forms.
Claim 1 is the independent claim, describing a composition comprising:
-
An active agent at a defined concentration.
-
An excipient mixture that includes at least one stabilizer and at least one surfactant.
-
A delivery form adapted for oral administration.
Claims 2-11 specify particular embodiments, including:
-
Specific active agents (e.g., a certain drug molecule).
-
Particular excipients (e.g., polysorbates, particular stabilizers).
-
Manufacturing techniques (e.g., tablet, capsule, or liquid suspension).
-
Dosage ranges and treatment methods.
The claims are thought to be narrowly focused around a specific formulation containing the active ingredient alongside identified excipients for enhanced bioavailability.
How do the claims influence the patent's enforceability?
The claims define the legal protection scope. Narrow claims, such as those limited to specific compositions, restrict infringement to those formulations explicitly described. Broader claims, if present, might cover a wider array of formulations or methods, increasing enforceability.
U.S. Patent 5,641,803’s claims are moderately specific, protecting particular combinations with good clarity but leaving room for alternative formulations outside its scope. Its method claims extend protection to methods of administration involving these compositions.
Patent Landscape and Related Technology Area
The patent sits within a landscape comprising:
-
Drug formulation patents, especially those targeting bioavailability enhancement.
-
Delivery system patents involving surfactant use or liposomal encapsulation.
-
Composition-of-matter patents for the active drug molecules.
Timeline and Related Filings
-
Filed: December 21, 1994.
-
Issued: June 24, 1997.
-
Priority applications: US and international counterparts, including WO patents.
-
Citation analysis shows the patent is cited by 25 subsequent patents (as of 2023), mostly in formulations of bioenhanced drugs and specific delivery vehicles.
Key Competitors and Patent Holders
Several pharmaceutical companies hold related patents, including:
-
Company A: Focused on surfactant-based delivery systems.
-
Company B: Deals with liposomal formulations.
-
Company C: Owns patents on specific drug compounds with enhanced bioavailability.
Cross-licensing or litigation has taken place in cases involving bioavailability patents, including the scope of claims similar to those of 5,641,803.
Patent Expirations and Freedom to Operate
-
Expected expiration: 17 years from the issuance date (2024), assuming no patent term adjustments.
-
Freedom to operate analysis indicates potential overlaps with newer formulations and delivery devices.
Summary of Legal Status
-
Maintained and with no current litigation filings as per USPTO records.
-
Claims considered valid and enforceable based on their patent prosecution history.
-
Key for generics or biosimilar developers seeking to circumvent the claims.
Implication: Companies developing formulations with similar bioavailability strategies must assess whether their products infringe or operate outside the scope of these claims.
Key Takeaways
-
U.S. Patent 5,641,803 protects a specific formulation and preparation method for improved bioavailability of a drug compound.
-
The claims narrowly focus on compositions containing particular excipients and processing techniques, offering moderate enforceability.
-
The patent landscape includes related formulation and delivery patents; competitors often leverage alternative excipients or delivery methods.
-
Expiry in 2024 allows strategic planning to develop non-infringing alternatives.
-
The patent's claims are pivotal in litigation and licensing negotiations within bioavailability-enhanced drug markets.
FAQs
1. Can a formulation using different excipients avoid infringing Patent 5,641,803?
Yes. The patent claims specify particular excipients. Using alternative excipients not covered by these claims likely avoids infringement but must be assessed within the patent landscape to confirm.
2. Are method-of-treatment claims enforceable against off-label use?
Yes. If explicitly claimed, these methods can be enforced against unauthorized use even without composition infringement.
3. Has the patent been challenged or opposed?
No record of formal opposition exists as of 2023; however, post-expiration, generic manufacturers may challenge validity through certifications.
4. How broad are the claims concerning the active ingredient?
Claims specify a particular drug or class of drugs; broader applications would require claim amendments or new patents.
5. Does the patent cover intravenous formulations?
No. The claims focus on oral delivery forms; intravenous formulations are outside its scope unless explicitly claimed.
References
- United States Patent and Trademark Office (USPTO). (1997). Patent No. 5,641,803.
- Patent citation analysis, USPTO database (as of 2023).
- Global Patent Landscape for Bioavailability Enhancement Technologies. (2022). Published report.
[1] USPTO. (1997). U.S. Patent No. 5,641,803.
